Adezunap clinical trials
How each study uses adezunap is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the adezunap studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Adezunap (AP707)
- 7
By phase
A phase 1/2 study counts in both.
- Phase 3
- 7
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Apurano Pharmaceuticals GmbH (7)
Studies
Open first, then newest update. How each study uses adezunap is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic PolyneuropathyRecruitingPhase 3Apurano Pharmaceuticals GmbHNCT06072573Written as Adezunap (AP707)
- Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back PainRecruitingPhase 3Apurano Pharmaceuticals GmbHNCT06071962Written as Adezunap (AP707)
- Efficacy and Tolerability of AP707 in Patients With Chronic Back PainRecruitingPhase 3Apurano Pharmaceuticals GmbHNCT06072560Written as Adezunap (AP707)
- Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any GenesisRecruitingPhase 3Apurano Pharmaceuticals GmbHNCT06072001Written as Adezunap (AP707)
- Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic PolyneuropathyRecruitingPhase 3Apurano Pharmaceuticals GmbHNCT06071975Written as Adezunap (AP707)
- Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral NeuropathyRecruitingPhase 3Apurano Pharmaceuticals GmbHNCT06071936Written as Adezunap (AP707)
- Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral NeuropathyRecruitingPhase 3Apurano Pharmaceuticals GmbHNCT06071988Written as Adezunap (AP707)